<DOC>
	<DOCNO>NCT00979212</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy ( CT ) , paclitaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy ( RT ) use high-energy x-ray kill tumor cell . Monoclonal antibody , panitumumab , block tumor growth different way . Some block ability tumor cell grow spread . Others find tumor cell help kill carry tumor-killing substance . Giving treatment surgery may make tumor small reduce amount normal tissue need remove . It yet know whether chemotherapy radiation therapy effective give without panitumumab treat patient non-small cell lung cancer . PURPOSE : This randomized phase II trial study chemotherapy radiation therapy see well work give without panitumumab treat patient stage IIIA non-small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy Radiation Therapy With Without Panitumumab Treating Patients With Stage IIIA Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine mediastinal nodal clearance completion induction chemoradiotherapy without panitumumab patient stage IIIA non-small cell lung cancer . Secondary - Assess overall survival patient . - Evaluate pattern first failure patient . - Determine acute late adverse event associate regimen . - Assess surgical morbidity patient resectable disease reassessment . - Determine correlation pre- post-treatment biomarkers ( include epidermal growth factor receptor ( EGFR ) ras mutation status ) outcome ( mediastinal nodal clearance overall survival ) . - Evaluate prognostic value plasma osteopontin microRNA overall survival . - Assess ability FDG-PET/CT scan re-staging predict outcome . OUTLINE : This multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive induction therapy comprise paclitaxel IV 1 hour carboplatin IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 . Patients also undergo intensity-modulated radiotherapy ( IMRT ) 3-dimensional conformal radiotherapy ( 3D-CRT ) daily day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , 36-40 . Beginning approximately 6-12 week later , patient receive consolidation therapy comprise paclitaxel IV 1 hour carboplatin IV 30 minute day 1 21 . - Arm II : Patients receive induction therapy comprise panitumumab IV 1 hour day 1 , 8 , 15 , 22 , 29 , 36 paclitaxel IV 1 hour carboplatin IV 30 minute day 8 , 15 , 22 , 29 , 36 . Patients also undergo IMRT 3D-CRT daily day 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 . Beginning approximately 6-12 week later , patient receive consolidation therapy comprise paclitaxel IV 1 hour carboplatin IV 30 minute day 1 21 . - In arm , patient resectable disease disease progression may proceed surgery ( thoracotomy , lobectomy , pneumonectomy ) approximately 4-6 week completion induction therapy . After surgery , patient proceed consolidation therapy . After completion study treatment , patient follow 6 week , every 3 month 1 year , every 6 month 2 year , annually thereafter .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* nonsmall cell lung cancer ( NSCLC ) , include follow histology : Adenocarcinoma Adenosquamous Large cell carcinoma Squamous cell carcinoma Nonlobar nondiffuse bronchoalveolar cell carcinoma NSCLC otherwise specify NOTE : *Documentation NSCLC may originate mediastinal node biopsy aspiration Stage IIIA ( T1T3 ) disease single primary lung parenchymal lesion AND positive ipsilateral mediastinal node node ( N2 ) without positive ipsilateral hilar node ( N1 ) N2 node must separate primary tumor either CT scan surgical exploration Maximum nodal diameter involve N2 node exceed 3.0 cm N2 status must pathologically confirm positive one follow methods* : Mediastinoscopy Mediastinotomy ( Chamberlain procedure ) Transesophageal needle biopsy use endoscopic ultrasound ( EUSTBNA ) Endobronchial ultrasound biopsy use endoscopic ultrasound guidance ( EBUSTBNA ) Thoracotomy Videoassisted thoracoscopy Transbronchial needle biopsy Wang technique ( TBNA ) Fineneedle aspiration CT guidance NOTE : *PET positivity ipsilateral mediastinal lymph node sufficient establish N2 nodal status Ipsilateral mediastinal node associate rightsided tumor must biopsied unless follow true : Tumor leave sided Paralyzed leave true vocal cord document bronchoscopy indirect laryngoscopy Nodes visible anterior/posterior ( level 5 ) region CT scan Distinct primary tumor separate node visible CT scan Histologic ( biopsy ) cytologic ( needle aspiration sputum ) proof nonsmall cell histology primary tumor If lymph node contralateral mediastinum neck visible contrast CT scan chest &gt; 1.0 cm short axis contralateral involvement suggest PET scan , node must confirm negative Measurable disease determine contrastenhanced CT scan Primary lung tumor distinct mediastinal lymph node If pleural effusion present , follow criterion must meet exclude malignant involvement ( incurable M1a disease ) : When pleural fluid visible CT scan chest xray , pleuracentesis require confirm pleural fluid cytologically negative . Exudative pleural effusion exclude , regardless cytology ; Effusions minimal ( i.e . visible ultrasound guidance ) small safely tap eligible . No palpable lymph node supraclavicular area higher neck , unless prove benign fineneedle aspiration biopsy No distant metastases PATIENT CHARACTERISTICS : Zubrod performance status 01 Absolute neutrophil count ( ANC ) ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Hemoglobin ≥ 10.0 g/dL ( transfusion allow ) Creatinine clearance ≥ 60 mL/min Total bilirubin ≤ 1.5 time upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Serum albumin &gt; 3.0 g/dL Serum magnesium normal ( supplementation allow ) Not pregnant Negative pregnancy test Fertile patient must use effective contraception 6 month completion treatment Forced expiratory volume one second ( FEV1 ) ≥ 2.0 L OR predict postresection FEV1 ≥ 0.8 L Diffusion capacity ≥ 50 % predict No invasive malignancy within past 3 year , except nonmelanoma skin cancer carcinoma situ breast , oral cavity , cervix No severe , active comorbidity , include follow : Current uncontrolled cardiac disease ( e.g. , uncontrolled hypertension , unstable angina , myocardial infarction within past 6 month , uncontrolled congestive heart failure , cardiomyopathy decrease ejection fraction ( &lt; 50 % ) Acute bacterial fungal infection require IV antibiotic Chronic obstructive pulmonary disease exacerbation respiratory illness require hospitalization would preclude study therapy within past 4 week Hepatic insufficiency result clinical jaundice and/or coagulation defect AIDS know HIV positivity No unintentional weight loss ≥ 5 % body weight within past 6 month No prior severe infusion reaction monoclonal antibody No preexist peripheral neuropathy ≥ grade 2 PRIOR CONCURRENT THERAPY : No prior systemic chemotherapy biological therapy ( include erlotinib hydrochloride similar agent ) study cancer Prior chemotherapy different cancer allow No prior radiotherapy region study cancer would result overlap radiotherapy field No prior therapy specifically directly target EGFR pathway</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
</DOC>